Norwood to back animal conservation research
07 April, 2004 by Melissa TrudingerMelbourne biotech Norwood Abbey (ASX:NAL) is to sponsor a Monash Institute of Reproduction and Development group dedicated to research into the conservation and preservation of Australian animals.
GroPep cans ulcer treatment after Phase II
07 April, 2004 by Graeme O'NeillAdelaide biotech GroPep (ASX:GRO) has yanked its potential topical treatment for chronic venous ulcers after inconclusive results from a Phase II clinical trial.
Biosignal lists on ASX at premium
06 April, 2004 by Renate KrelleBiosignal (ASX:BOS) listed today on the Australian Stock Exchange, with shares leaping to AUD$0.38, a premium of almost 100 per cent on its $0.20 issue price.
New neuro labs open in Melbourne
06 April, 2004 by Melissa TrudingerA state-of-the-art cellular neurophysiology laboratory was opened today at the University of Melbourne for the National Neuroscience Facility (NNF).
GeneTraks picks up $1m grant
06 April, 2004 by Melissa TrudingerBrisbane-based GeneTraks has received a $1 million R&D Start grant from the Commonwealth government for its AUD$2.6 million equine diagnostics development project.
Phosphagenics claims success in morphine trial
06 April, 2004 by Renate KrellePhosphagenics (ASX:POH) -– formerly Vital Capital -– has announced the successful completion of animal studies for its transdermal delivery system for morphine.
Biotopya entrepreneurs blitz awards, sell company
05 April, 2004 by Melissa TrudingerA company formed as part of the Victorian Biotechnology Entrepreneur Program, a pilot program of Young Achievers Australia and the Victorian State Government, has returned a whopping 900 per cent to its shareholders, through the sale of its products to a scientific supplies company.
Norwood Immunology to list in UK, raising $37 million
05 April, 2004 by Melissa TrudingerNorwood Abbey's UK subsidiary Norwood Immunology has revealed its plans to float on the London Stock Exchange's Alternative Investment Market (AIM) in May.
Biosignal raises $4 million, readies itself to list next week
02 April, 2004 by Renate KrelleThe first NSW biotechnology listing of 2004 is on the launch pad. Rather than listing in an IPO, Sydney-based BioSignal has chosen to make its debut via the back door, using as its vehicle Perth-based CTI Communications, which yesterday raised $4 million in an oversubscribed share issue and will acquire 100 percent of BioSignal’s shares.
Bresagen restructure and relisting plans announced
02 April, 2004 by Melissa TrudingerBresagen's administrators have reached an in-principle agreement with Queensland-based public unlisted biotech company CBio for the restructure and relisting of the company.
Bionomics raises $4 million for epilepsy and anxiety drug program
01 April, 2004 by Graeme O'NeillAdelaide biotech Bionomics’ (ASX:BNO, OTC:BMICY) successful share placement last month has raised nearly $4 million of the $6 million needed to fast-track its epilepsy and anxiety-drug discovery program, while causing minimal angst among shareholders.
Eiffel to focus on developing inhaled and transdermal insulin
31 March, 2004 by Renate KrelleEiffel Technologies (ASX : EIF) announced today it has completed further animal studies in its development of improved injectable insulin, and would focus resources on collaborations with pharmaceutical companies working on inhaled or transdermal insulin.
QRxPharma's opioid greater than the sum of its parts
31 March, 2004 by Renate KrelleMinimising the side-effects that plague patients taking opioid pain-relievers will be the big advantage of Queensland-based QRxPharma’s novel opioid candidate Q8003, according to Alex Baker, Program Manager at QRxPharma.
Southpoint acquires Boron molecular
30 March, 2004 by Melissa TrudingerFormer Perth-based telecommunications company Southpointe (ASX: SOU) plans to become a biotechnology investment company after acquiring interests in two biotechnology-related ventures.
VRI to raise $2.9 million
30 March, 2004 by Melissa TrudingerVRI Biomedical has announced plans to raise up to AUD$2.9 million through a just completed share placement and a non-renounceable rights issue to be put towards production and marketing of the company's proTract probiotic products.
